Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 10/20 | 0.42 |
| ▸ | CNR1 | P21554 | 4/20 | 0.42 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.39 |
| ▸ | P2RX7 | Q99572 | 2/20 | 0.38 |
| ▸ | EPHX2 | P34913 | 3/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3743041 | 0.71 | CNR2 (0.46) | CNR2CNR1ADORA1P2RX7EPHX2 | |
| SCHEMBL3804786 | 0.71 | CNR2 (0.58) | CNR2CNR1ADORA1P2RX7ALDH1A1 | |
| SCHEMBL4086454 | 0.71 | CNR2 (0.58) | CNR2CNR1ADORA1P2RX7ALDH1A1 | |
| SCHEMBL4092598 | 0.68 | CNR2 (0.47) | CNR2CNR1ADORA1 | |
| SCHEMBL1053446 | 0.68 | ADORA1 (0.49) | CNR2CNR1ADORA1P2RX7EPHX2 | |
| SCHEMBL3802009 | 0.68 | CNR2 (0.55) | CNR2CNR1ADORA1P2RX7 | |
| SCHEMBL3646676 | 0.68 | CNR2 (0.55) | CNR2CNR1ADORA1P2RX7 | |
| SCHEMBL4095673 | 0.67 | CNR2 (0.76) | CNR2CNR1ALDH1A1LMNA | |
| SCHEMBL4091428 | 0.66 | CNR2 (0.50) | CNR2CNR1ADORA1ALDH1A1 | |
| SCHEMBL4095389 | 0.66 | CNR2 (0.41) | CNR2CNR1ADORA1P2RX7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8835475-B2 | Compounds as cannabinoid receptor ligands | ABBVIE INC. (US) | 2014-09-16 | — | — | US | disclosed |
| US-8501794-B2 | Compounds as cannabinoid receptor ligands | ABBVIE INC. (US) | 2013-08-06 | — | — | US | disclosed |
| US-20110082116-A1 | NOVEL COMPOUNDS AS CANNABINOID RECEPTOR LIGANDS | ABBOTT LABORATORIES (US) | 2011-04-07 | — | — | US | disclosed |
| US-7872033-B2 | N-[(5Z)-4-butyl-2-tert-butylisothiazol-5(2H)-ylidene]-5-chloro-2-methoxybenzamide; CB2 receptors ligand; antiinflammatory, analgesic agent; autoimmune diseases; neuroprotectants | ABBOTT LABORATORIES (US) | 2011-01-18 | — | — | US | disclosed |
| US-20100234345-A1 | NOVEL COMPOUNDS AS CANNABINOID RECEPTOR LIGANDS | ABBOTT LABORATORIES (US) | 2010-09-16 | — | — | US | disclosed |
| US-20090023789-A1 | N-[(5Z)-4-butyl-2-tert-butylisothiazol-5(2H)-ylidene]-5-chloro-2-methoxybenzamide; CB2 receptors ligand; antiinflammatory, analgesic agent; autoimmune diseases; neuroprotectants | ABBOTT LABORATORIES (US) | 2009-01-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090023789-A1 | N-[(5Z)-4-butyl-2-tert-butylisothiazol-5(2H)-ylidene]-5-chloro-2-methoxybenzamide; CB2 receptors ligand; antiinflammatory, analgesic agent; autoimmune diseases; neuroprotectants | CNR2, CNR1, TBXA2R | CNR2 1/4885CNR1 2/4885ADORA1 389/4885 |
| US-20110082116-A1 | NOVEL COMPOUNDS AS CANNABINOID RECEPTOR LIGANDS | CNR1, CNR2, GPR18 | CNR2 2/4885CNR1 1/4885ADORA1 424/4885 |
| US-20100234345-A1 | NOVEL COMPOUNDS AS CANNABINOID RECEPTOR LIGANDS | CNR1, CNR2, GPR18 | CNR2 2/4885CNR1 1/4885ADORA1 421/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.